M. Miravitlles

First name
Last name
Chen, S., Miravitlles, M., Rhee, C. K., Pavord, I. D., Jones, R., Carter, V., et al. (2022). Patients with Chronic Obstructive Pulmonary Disease and Evidence of Eosinophilic Inflammation Experience Exacerbations Despite Receiving Maximal Inhaled Maintenance Therapy. Int J Chron Obstruct Pulmon Dis, 17, 2187-2200. http://doi.org/10.2147/copd.s378649
Mullerova, H., Chigbo, C., Hagan, G. W., Woodhead, M. A., Miravitlles, M., Davis, K. J., & Wedzicha, J. A. (2012). The natural history of community-acquired pneumonia in COPD patients: a population database analysis. Respir Med. http://doi.org/10.1016/j.rmed.2012.04.008
van Boven, J., Benhaddi, H., Roche, N., Bjermer, L., Miravitlles, M., Voorham, J., & Price, D. (2017). Real-world cost effectiveness comparison of symbicort turbuhaler and duoresp spiromax in UK patients with asthma or chronic obstructive pulmonary disease. Value in Health.
Voorham, J., Roche, N., Benhaddi, H., van der Tol, M., Carter, V., van Boven, J. F. M., et al. (2018). Real-world effectiveness evaluation of budesonide/formoterol Spiromax for the management of asthma and chronic obstructive pulmonary disease in the UK. BMJ Open. http://doi.org/10.1136/bmjopen-2018-022051
Kerkhof, M., Chaudhry, I., Pavord, I. D., Miravitlles, M., Rhee, K., Halpin, D. M. G., et al. (2020). Blood eosinophil count predicts treatment failure and hospital readmission for COPD. ERJ Open Res. http://doi.org/10.1183/23120541.00188-2020